Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity.

Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ.

Nat Commun. 2018 Jun 18;9(1):2368. doi: 10.1038/s41467-018-04413-3.

2.

Quantifying climate feedbacks in polar regions.

Goosse H, Kay JE, Armour KC, Bodas-Salcedo A, Chepfer H, Docquier D, Jonko A, Kushner PJ, Lecomte O, Massonnet F, Park HS, Pithan F, Svensson G, Vancoppenolle M.

Nat Commun. 2018 May 15;9(1):1919. doi: 10.1038/s41467-018-04173-0. Review.

3.

A robust empirical seasonal prediction of winter NAO and surface climate.

Wang L, Ting M, Kushner PJ.

Sci Rep. 2017 Mar 21;7(1):279. doi: 10.1038/s41598-017-00353-y.

4.

Atmospheric dynamics. Constrained work output of the moist atmospheric heat engine in a warming climate.

Laliberté F, Zika J, Mudryk L, Kushner PJ, Kjellsson J, Döös K.

Science. 2015 Jan 30;347(6221):540-3. doi: 10.1126/science.1257103.

5.

Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.

Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ.

Breast Cancer Res Treat. 2008 May;109(2):241-50. Epub 2007 Jul 19.

PMID:
17638070
6.

Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.

Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ.

Breast Cancer Res Treat. 2007 Nov;105(3):297-309. Epub 2006 Dec 21.

PMID:
17186358
7.

p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.

Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME.

Mol Endocrinol. 2006 May;20(5):971-83. Epub 2006 Jan 12.

PMID:
16410316
8.

Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG.

Cancer Res. 2005 Aug 1;65(15):6557-67.

10.

ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus.

Webb P, Valentine C, Nguyen P, Price RH Jr, Marimuthu A, West BL, Baxter JD, Kushner PJ.

Nucl Recept. 2003 Jun 28;1(1):4.

11.

Design of thyroid hormone receptor antagonists from first principles.

Webb P, Nguyen NH, Chiellini G, Yoshihara HA, Cunha Lima ST, Apriletti JW, Ribeiro RC, Marimuthu A, West BL, Goede P, Mellstrom K, Nilsson S, Kushner PJ, Fletterick RJ, Scanlan TS, Baxter JD.

J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. Review.

PMID:
12650702
12.

Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

Webb P, Nguyen P, Kushner PJ.

J Biol Chem. 2003 Feb 28;278(9):6912-20. Epub 2002 Dec 13.

13.

Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG, Kushner PJ.

J Biol Chem. 2002 Jul 5;277(27):24353-60. Epub 2002 May 1.

14.

Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist.

Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S.

Endocrinology. 2002 Feb;143(2):517-24.

PMID:
11796506
15.

p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Cancer Res. 2002 Jan 1;62(1):141-51.

16.

Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity.

Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ.

J Biol Chem. 2001 Jun 22;276(25):22177-82. Epub 2001 Apr 11.

17.

Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.

Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG.

J Biol Chem. 2001 May 25;276(21):18375-83. Epub 2001 Mar 9.

18.

Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Oncogene. 2001 Jan 4;20(1):77-87.

19.

Estrogen receptor pathways to AP-1.

Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7. Review.

PMID:
11162939
20.

Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.

Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ.

Mol Endocrinol. 2001 Jan;15(1):32-45.

PMID:
11145737
21.

The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs).

Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ.

Mol Endocrinol. 2000 Dec;14(12):1976-85.

PMID:
11117528
22.

An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen.

Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ.

J Biol Chem. 2000 Dec 1;275(48):37552-8.

23.

Oestrogen receptor function at classical and alternative response elements.

Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G.

Novartis Found Symp. 2000;230:20-6; discussion 27-40. Review.

PMID:
10965500
24.

Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

An J, Ribeiro RC, Webb P, Gustafsson JA, Kushner PJ, Baxter JD, Leitman DC.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15161-6.

25.

The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ.

Mol Endocrinol. 1999 Oct;13(10):1672-85.

PMID:
10517669
26.

Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins.

Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR.

Mol Cell Biol. 1999 Sep;19(9):6164-73.

27.

Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.

Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, Kushner PJ.

Mol Endocrinol. 1999 Jun;13(6):897-909.

PMID:
10379889
28.

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC.

Clin Cancer Res. 1999 Feb;5(2):251-6.

29.

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL.

Cell. 1998 Dec 23;95(7):927-37.

30.

Molecular and structural biology of thyroid hormone receptors.

Apriletti JW, Ribeiro RC, Wagner RL, Feng W, Webb P, Kushner PJ, West BL, Nilsson S, Scanlan TS, Fletterick RJ, Baxter JD.

Clin Exp Pharmacol Physiol Suppl. 1998 Nov;25:S2-11. Review.

PMID:
9809185
31.

Structure and specificity of nuclear receptor-coactivator interactions.

Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR.

Genes Dev. 1998 Nov 1;12(21):3343-56.

32.

Estrogen receptor activation function 1 works by binding p160 coactivator proteins.

Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ.

Mol Endocrinol. 1998 Oct;12(10):1605-18.

PMID:
9773983
33.

Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies.

Ribeiro RC, Apriletti JW, Wagner RL, West BL, Feng W, Huber R, Kushner PJ, Nilsson S, Scanlan T, Fletterick RJ, Schaufele F, Baxter JD.

Recent Prog Horm Res. 1998;53:351-92; discussion 392-4. Review.

PMID:
9769715
34.

X-ray crystallographic and functional studies of thyroid hormone receptor.

Ribeiro RC, Apriletti JW, Wagner RL, Feng W, Kushner PJ, Nilsson S, Scanlan TS, West BL, Fletterick RJ, Baxter JD.

J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):133-41. Review.

PMID:
9699866
35.

Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors.

Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL.

Science. 1998 Jun 12;280(5370):1747-9.

36.
37.

Estrogen receptor accessory proteins augment receptor-DNA interaction and DNA bending.

Landel CC, Potthoff SJ, Nardulli AM, Kushner PJ, Greene GL.

J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):59-73.

PMID:
9449207
38.

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS.

Science. 1997 Sep 5;277(5331):1508-10.

39.

Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity.

Saatcioglu F, Lopez G, West BL, Zandi E, Feng W, Lu H, Esmaili A, Apriletti JW, Kushner PJ, Baxter JD, Karin M.

Mol Cell Biol. 1997 Aug;17(8):4687-95.

40.
41.

Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis.

Seielstad DA, Carlson KE, Kushner PJ, Greene GL, Katzenellenbogen JA.

Biochemistry. 1995 Oct 3;34(39):12605-15.

PMID:
7548010
42.

Estrogen receptor accessory proteins: effects on receptor-DNA interactions.

Landel CC, Kushner PJ, Greene GL.

Environ Health Perspect. 1995 Oct;103 Suppl 7:23-8.

43.

Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.

Cavaillès V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG.

EMBO J. 1995 Aug 1;14(15):3741-51.

44.

Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli.

Seielstad DA, Carlson KE, Katzenellenbogen JA, Kushner PJ, Greene GL.

Mol Endocrinol. 1995 Jun;9(6):647-58.

PMID:
8592511
45.
46.

Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein.

Sadovsky Y, Webb P, Lopez G, Baxter JD, Fitzpatrick PM, Gizang-Ginsberg E, Cavailles V, Parker MG, Kushner PJ.

Mol Cell Biol. 1995 Mar;15(3):1554-63.

47.

Screening and characterization of estrogenic activity from a hydroxystilbene library.

Williard R, Jammalamadaka V, Zava D, Benz CC, Hunt CA, Kushner PJ, Scanlan TS.

Chem Biol. 1995 Jan;2(1):45-51.

48.

The nuclear hormone receptor gene superfamily.

Ribeiro RC, Kushner PJ, Baxter JD.

Annu Rev Med. 1995;46:443-53. Review.

PMID:
7598477
49.

The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins.

Landel CC, Kushner PJ, Greene GL.

Mol Endocrinol. 1994 Oct;8(10):1407-19.

PMID:
7854357
50.

Eukaryotic regulatory elements lurking in plasmid DNA: the activator protein-1 site in pUC.

Kushner PJ, Baxter JD, Duncan KG, Lopez GN, Schaufele F, Uht RM, Webb P, West BL.

Mol Endocrinol. 1994 Apr;8(4):405-7. Review. No abstract available.

PMID:
8052261

Supplemental Content

Loading ...
Support Center